Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to support the Medicines and Healthcare products Regulatory Agency (MHRA) to uphold quality and safety standards following the UK’s withdrawal from the EU.

The Medicines and Healthcare products Regulatory Agency (MHRA) has made preparations to amend medicines and medical devices regulations to make sure we have the strongest regulatory framework for medicines from day 1 after the end of the transition period, This will enable the MHRA to continue to have the appropriate oversight for medicines placed on the market, to maintain patient safety and be able to take action where necessary.

After the transition period, our aim is to make sure patients in the United Kingdom continue to be able to access the best and most innovative medicines and medical devices. We want patients to be reassured that their safety will be protected through the strongest regulatory framework.